R&D

News

Secretive Moderna could finally go public with $500m IPO

RNA medicine specialist Moderna is attempting the biggest IPO in biotech history, after applying to raise $500 million from investors.

News

Gilead pushes on with NASH drug after phase 2 success

Gilead Sciences presented promising data on its research into advanced fibrosis caused by non-alcoholic steatohepatitis (NASH), one of several big pharma companies developing drugs for the

Partner Content

Research Showcase launches new collaboration

Medicines Discovery Catapult and the National Centre for the Replacement, Refinement & Reduction of Animals

News

Machine learning tool aims to cut stress in clinical trial p...

Tech firm Cambridge Consultants has designed a digital health tool that aims to make clinical trials more efficient using machine learning to help prevent patients becoming stressed and dro

News

AbbVie, Roche eye first-line use of Venclexta in leukaemia

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.

News

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Magic mushroom drug could be depression breakthrough, says F...

The liberty cap mushroom, notoriously used illegally as a psychoactive drug, could be the inspiration for a new therapy for depression according to the US drug regulator.

Secretive Moderna could finally go public with $500m IPO

Gilead pushes on with NASH drug after phase 2 success

Research Showcase launches new collaboration

Machine learning tool aims to cut stress in clinical trial p...

AbbVie, Roche eye first-line use of Venclexta in leukaemia

Magic mushroom drug could be depression breakthrough, says F...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

R&amp;D

Editor's Picks

R&D